Emergent use of ticagrelor during endovascular reperfusion in large arterial occlusions

J Stroke Cerebrovasc Dis. 2023 Dec;32(12):107351. doi: 10.1016/j.jstrokecerebrovasdis.2023.107351. Epub 2023 Oct 12.

Abstract

Objective: Given many emerging indications for endovascular interventions in ischemic strokes, a safe and effective adjuvant antiplatelet regimen for acute revascularization has become a subject of interest. Ticagrelor is a direct oral P2Y12 inhibitor that may achieve rapid platelet suppression than standard oral therapies. We report our experience of Ticagrelor use in revascularization of acute large arterial steno-occlusive disease, describing procedural post-procedure thrombotic events, major hemorrhages, and other clinical outcomes.

Methods: This was a single-center retrospective case series of large steno-occlusive disease requiring endovascular reperfusion with emergent adjuvant Ticagrelor, defined as 30 min of the procedure from skin puncture to closure of the arteriotomy. Major outcomes investigated were thromboembolism in the target artery, and symptomatic intracranial or extracranial major hemorrhages. Additional analyses were performed with respect to timing of the administration and use of rescue GPIIb/IIIa inhibitors if any.

Results: 73 consecutive patients were identified, presenting with severe ischemic stroke (median NIHSS 16) of large artery origin. 67% required stent placement (45% cervical carotid, 22% intracranial artery), 9.5% angioplasty and 23% mechanical thrombectomy only. Two experienced symptomatic in-stent occlusion, and 7 experienced major hemorrhages (9.5%) including 3 fatal symptomatic intracranial hemorrhages (4.1%). Among 19 subjects (26%) who received pretreatment with Ticagrelor, there were fewer GPIIb/IIIa administration, angioplasty and stenting, without yielding benefit in functional outcome or mortality. GPIIb/IIIa was administered as rescue therapy in 45 subjects (62%), which was found associated with increased bleeding compared to patients receiving Ticagrelor only, in whom no bleeding complications were recorded (16% vs. 0%; p = 0.03).

Conclusion: We report our findings on Ticagrelor as an adjuvant antiplatelet therapy in ischemic stroke of large arterial origin requiring emergent revascularization. Effectiveness, safety, need for additional rescue treatment, and comparison to other commonly used oral antiplatelets should be investigated in future prospective studies.

Keywords: Antithrombotics; Ischemic stroke; Large arterial occlusions; Mechanical thrombectomes.

MeSH terms

  • Arterial Occlusive Diseases* / therapy
  • Endovascular Procedures* / adverse effects
  • Endovascular Procedures* / methods
  • Humans
  • Intracranial Hemorrhages / etiology
  • Ischemic Stroke* / complications
  • Reperfusion / adverse effects
  • Retrospective Studies
  • Stents
  • Stroke* / diagnosis
  • Stroke* / drug therapy
  • Thrombectomy / adverse effects
  • Thrombectomy / methods
  • Ticagrelor / adverse effects
  • Treatment Outcome

Substances

  • Ticagrelor